Advanced search
1 file | 190.55 KB Add to list

Prevention and treatment of renal osteodystrophy in children on chronic renal failure : European guidelines

(2006) PEDIATRIC NEPHROLOGY. 21(2). p.151-159
Author
Organization
Abstract
Childhood renal osteodystrophy (ROD) is the consequence of disturbances of the calcium-regulating hormones vitamin D and parathyroid hormone (PTH) as well as of the somatotroph hormone axis associated with local modulation of bone and growth cartilage function. The resulting growth retardation and the potentially rapid onset of ROD in children are different from ROD in adults. The biochemical changes of ROD as well as its prevention and treatment affect calcium and phosphorus homeostasis and are directly associated with the development of cardiovascular disease in pediatric renal patients. The aims of the clinical and biochemical surveillance of pediatric patients with CRF or on dialysis are prevention of hyperphosphatemia, avoidance of hypercalcemia and keeping the calcium phosphorus product below 5 mmol(2)/l(2). The PTH levels should be within the normal range in chronic renal failure (CRF) and up to 2-3 times the upper limit of normal levels in dialysed children. Prevention of ROD is expected to result in improved growth and less vascular calcification.
Keywords
secondary hyperparathyroidism, chronic renal failure, calcium-phosphate product, vitamin D, parathyroidectomy, CHRONIC PERITONEAL-DIALYSIS, INTERMITTENT CALCITRIOL THERAPY, PARATHYROID-HORMONE LEVELS, SECONDARY HYPERPARATHYROIDISM, HEMODIALYSIS-PATIENTS, PEDIATRIC-PATIENTS, GROWTH-HORMONE, CALCIUM ACETATE, BONE TURNOVER, IMMUNORADIOMETRIC ASSAY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 190.55 KB

Citation

Please use this url to cite or link to this publication:

MLA
Klaus, G et al. “Prevention and Treatment of Renal Osteodystrophy in Children on Chronic Renal Failure : European Guidelines.” PEDIATRIC NEPHROLOGY 2006 : 151–159. Print.
APA
Klaus, G., Watson, A., Edefonti, A., Fischbach, M., Rönnholm, K., Schaefer, F., Simkova, E., et al. (2006). Prevention and treatment of renal osteodystrophy in children on chronic renal failure : European guidelines. PEDIATRIC NEPHROLOGY.
Chicago author-date
Klaus, G, A Watson, A Edefonti, M Fischbach, K Rönnholm, F Schaefer, E Simkova, et al. 2006. “Prevention and Treatment of Renal Osteodystrophy in Children on Chronic Renal Failure : European Guidelines.” Pediatric Nephrology.
Chicago author-date (all authors)
Klaus, G, A Watson, A Edefonti, M Fischbach, K Rönnholm, F Schaefer, E Simkova, CJ Stefanidis, V Strazdins, Johan Vande Walle, C Schröder, A Zurowska, and M Ekim. 2006. “Prevention and Treatment of Renal Osteodystrophy in Children on Chronic Renal Failure : European Guidelines.” Pediatric Nephrology.
Vancouver
1.
Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure : European guidelines. PEDIATRIC NEPHROLOGY. 2006. p. 151–9.
IEEE
[1]
G. Klaus et al., “Prevention and treatment of renal osteodystrophy in children on chronic renal failure : European guidelines,” PEDIATRIC NEPHROLOGY, vol. 21, no. 2. pp. 151–159, 2006.
@misc{4128939,
  abstract     = {Childhood renal osteodystrophy (ROD) is the consequence of disturbances of the calcium-regulating hormones vitamin D and parathyroid hormone (PTH) as well as of the somatotroph hormone axis associated with local modulation of bone and growth cartilage function. The resulting growth retardation and the potentially rapid onset of ROD in children are different from ROD in adults. The biochemical changes of ROD as well as its prevention and treatment affect calcium and phosphorus homeostasis and are directly associated with the development of cardiovascular disease in pediatric renal patients. The aims of the clinical and biochemical surveillance of pediatric patients with CRF or on dialysis are prevention of hyperphosphatemia, avoidance of hypercalcemia and keeping the calcium phosphorus product below 5 mmol(2)/l(2). The PTH levels should be within the normal range in chronic renal failure (CRF) and up to 2-3 times the upper limit of normal levels in dialysed children. Prevention of ROD is expected to result in improved growth and less vascular calcification.},
  author       = {Klaus, G and Watson, A and Edefonti, A and Fischbach, M and Rönnholm, K and Schaefer, F and Simkova, E and Stefanidis, CJ and Strazdins, V and Vande Walle, Johan and Schröder, C and Zurowska, A and Ekim, M},
  issn         = {0931-041X},
  keywords     = {secondary hyperparathyroidism,chronic renal failure,calcium-phosphate product,vitamin D,parathyroidectomy,CHRONIC PERITONEAL-DIALYSIS,INTERMITTENT CALCITRIOL THERAPY,PARATHYROID-HORMONE LEVELS,SECONDARY HYPERPARATHYROIDISM,HEMODIALYSIS-PATIENTS,PEDIATRIC-PATIENTS,GROWTH-HORMONE,CALCIUM ACETATE,BONE TURNOVER,IMMUNORADIOMETRIC ASSAY},
  language     = {eng},
  number       = {2},
  pages        = {151--159},
  series       = {PEDIATRIC NEPHROLOGY},
  title        = {Prevention and treatment of renal osteodystrophy in children on chronic renal failure : European guidelines},
  url          = {http://dx.doi.org/10.1007/s00467-005-2082-7},
  volume       = {21},
  year         = {2006},
}

Altmetric
View in Altmetric
Web of Science
Times cited: